Unresectable Pancreatic Cancer
Conditions
Interventions
multicenter HLA-blinded study: patients will be vaccinated biweekly with peptide vaccine
Sponsors
Yamaguchi University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Continuous administration the peptide vaccine for patients who dropped out the VENUS-PC study (2)ECOG Performance Status must be 0,1,2 or 3 (3)Measureable region evaluable according to the RECIST(ver.1.1) (4)Patient's condition is keeping within grade 3 hematological toxicity and within grade2 non-hematological toxicity . (CTCAE ver. 4.0) (5)Patients must have signed the consent form.
Exclusion criteria
Exclusion criteria: (1) Active double cancer (include asynchronous double cancer with disease-free duration <=1 year) except carcinoma in situ or intramucosal cancer. (2) Interstitial pneumonia or pulmonary fibrosis. (3) Severe nervous disorder or mental disorder. (4)History of myocardial infarction, severe unstable angina pectoris, CABG, congestive heart failure, cerebrovascular accident, pulmonary embolism, deep-vein thrombosis, or other severe thromboembolism within 12 months (5) Allergy for using epitope peptides (6)Unhealed traumatic lesion, including traumatic fracture. (7)Pregnant females or nursing mothers who can not stop lactation after the recruitment. (8)The subject who was determined by investigator that being not adequate to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | — |
Countries
Japan
Contacts
Public ContactNobuaki Suzuki
Yamaguchi University Hospital Department of Surgery II
Outcome results
None listed